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Abstract
Background: Minor protease inhibitor (PI) mutations often exist as polymorphisms in HIV-1 sequences from treatment-naı ¨ve
patients. Previous studies showed that their presence impairs the antiretroviral treatment (ART) response. Evaluating these
findings in a larger cohort is essential.
Methods: To study the impact of minor PI mutations on time to viral suppression and time to virological failure, we included
patients from the Swiss HIV Cohort Study infected with HIV-1 subtype B who started first-line ART with a PI and two
nucleoside reverse transcriptase inhibitors. Cox regression models were performed to compare the outcomes among
patients with 0 and $1 minor PI mutation. Models were adjusted for baseline HIV-1 RNA, CD4 cell count, sex, transmission
category, age, ethnicity, year of ART start, the presence of nucleoside reverse transcriptase inhibitor mutations, and stratified
for the administered PIs.
Results: We included 1199 patients of whom 944 (78.7%) received a boosted PI. Minor PI mutations associated with the
administered PI were common: 41.7%, 16.1%, 4.7% and 1.9% had 1, 2, 3 or $4 mutations, respectively. The time to viral
suppression was similar between patients with 0 (reference) and $1 minor PI mutation (multivariable hazard ratio (HR): 1.1
[95% confidence interval (CI): 1.0–1.3], P=.196). The time to virological failure was also similar (multivariable HR:.9 [95%
CI:.5–1.6], P=.765). In addition, the impact of each single minor PI mutation was analyzed separately: none was significantly
associated with the treatment outcome.
Conclusions: The presence of minor PI mutations at baseline has no effect on the therapy outcome in HIV infected
individuals.
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Minor protease inhibitor (PI) mutations are very common
among treatment-naı ¨ve patients infected with HIV-1 but their
impact on treatment outcome is poorly understood [1,2,3,4,5,6].
The prevalence of different minor PI mutations among treatment-
naı ¨ve patients varies largely and is highly dependent on the HIV-1
subtype [7,8,9]. Some minor PI mutations occur as natural
polymorphisms whereas others do not occur in the absence of PI
therapy [10]. Minor PI mutations do not lead to high level
resistance when occurring alone but they either improve the viral
fitness or increase the drug resistance level in the presence of major
PI mutations [11,12]. Minor PI mutations are therefore also called
secondary or accessory mutations [13].
It was assumed that minor PI mutations among treatment-
naı ¨ve patients might facilitate the emergence of major PI
mutations and therefore lead to a worse therapeutic response to
PIs. Other studies analyzing this issue were quite controversial.
Perno et al. found evidence that the presence of minor PI
mutations, particularly at position 10 and 36, lead to early
treatment failure and to a higher number of acquired major PI
mutations at the time of treatment failure [14,15]. Other studies
found no evidence for an impaired treatment outcome
[16,17,18,19]. All these studies are limited by a rather small
sample size and mainly focus on response to unboosted PI
therapy which is no longer recommended [20].
Therefore, we aimed studying the impact of minor PI
mutations on virological outcome in first-line antiretroviral
therapy (ART) using the dataset of the Swiss HIV Cohort Study
(SHCS) [21].
Methods
Ethics Statement
The SHCS has been approved by the following ethical
committees of all participating institutions: Kantonale Ethikkom-
mission Bern; Ethikkommission beider Basel; comite ´ d’e ´thique du
de ´partement de me ´dicine de Ho ˆpitaux Universitaires de Gene `ve;
commission d’e ´thique de la recherche clinique, Lausanne;
comitato etico cantonale, Bellinzona; Ethikkommission des
Kanton St.Gallens; and Ethik-Kommission Zu ¨rich, all Switzer-
land. Written informed consent has been obtained from all
participants.
Study Population
We used data from the SHCS, a nationwide, multicenter, clinic-
based cohort with continuous enrolment and semi-annual study
visits. Data up to 13 September 2011 were considered. The SHCS
is very representative and includes about 66% of patients living
with AIDS in Switzerland and 75% of all patients receiving
antiretroviral therapy [21]. In addition, we used data from the
SHCS drug resistance database that includes sequences from all
authorized laboratories in Switzerland. Sequences are stored in
SmartGene’s (Zug, Switzerland) Integrated Database Network
System (IDNS version 3.6.5) [22].
Patient Selection and Study Design
We included HIV-1 subtype B infected individuals who started
first-line ART between 1 January 1999 and 1 July 2010 with an
unboosted PI or a boosted PI and two nucleoside reverse
transcriptase inhibitors (NRTIs) and who had CD4 cell counts
and HIV-1 plasma RNA levels measured before start of ART. A
genotypic resistance test performed while ART-naı ¨ve was an
additional inclusion criterion. Patients were excluded if they had
viruses with $1 transmitted major PI mutation or if they had no
HIV-1 RNA measured during first-line ART [23].
We studied the following endpoints: a) time to viral suppression,
b) time to virological failure, and c) accumulation of major
mutations at the time of virological failure. Time to viral
suppression was defined as the time to the first viral load ,50
copies/mL. Virological failure was defined as 2 consecutive values
.500 copies/mL after at least 180 days of continuous treatment,
1 value .500 after 180 days followed by a treatment change or no
viral suppression for more than 180 days. To fulfill the criteria of a
virological failure, patients needed a minimum time of follow-up,
therefore the analysis of time to virological failure was restricted to
patients with $1 HIV-1 RNA measurement after 180 days of
continuous treatment or to patients with $1 HIV-1 RNA
measurement after previous viral suppression. The accumulation
of major mutations at virological failure was studied in patients
who experienced a virological failure on first-line ART and who
had a genotypic resistance test performed between the virological
failure and treatment change.
Minor PI mutations were defined based on the IAS-USA
recommendations [23]. In the following we term mutations as
related to a specific drug if they are listed as minor PI mutations on
the IAS-USA drug resistance mutation list [23]. Minor PI
mutations related to the following PIs were analyzed: atazanavir
(L10I/F/V/C, G16E, K20R/M/I/T/V, L24I, V32I, L33I/F/V,
E34Q, M36I/L/V, M46I/L,G48V, F53L/Y, I54L/V/M/T/A,
D60E, I62V, I64L/M/V, A71V/I/T/L,G73C/S/T/A, V82A/
T/F/I, I85V, L90M, I93L/M), darunavir (V11I, V32I, L33F,
T74P, L89V), fosamprenavir (L10F/I/R/V, V32I, M46I/L,
I47V, I54L/V/M, G73S, L76V, V82A/F/S/T, L90M), indinavir
(L10I/R/V, K20M/R, L24I, V32I, M36I, I54V, A71V/T,
G73S/A, L76V, V77I, L90M), lopinavir (L10F/I/R/V, K20M/
R, L24I, L33F, M46I/L, I50V, F53L, I54V/L/A/M/T/S, L63P,
A71V/T, G73S, I84V, L90M), nelfinavir (L10F/I, M36I, M46I/
L, A71V/T, V77I, V82A/F/T/S, I84V, N88D/S) and saquinavir
(L10I/R/V, L24I, I54V/L, I62V, A71V/T, G73S, V77I, V82A/
F/T/S, I84V). No patient was treated with tipranavir.
Statistical Analysis
We performed Fisher’s exact tests and Wilcoxon rank sum
tests to compare categorical and continuous baseline character-
istics, respectively. We plotted Kaplan-Meier curves and used
log-rank tests to compare the virological outcome between
patients with and without minor PI mutations. In addition, we
performed univariable and multivariable Cox regression to
analyze the time to viral suppression and the time to virological
failure. Multivariable models were adjusted for the following
potential confounders: sex, ethnicity, age, transmission category,
baseline CD4 cell count, baseline HIV-1 RNA level, calendar
year of ART start and the presence of NRTI mutations [23] and
stratified for the PI used. Continuous variables were categorized
if likelihood ratio tests showed significant departure from
linearity. Follow-up was censored when first-line ART was
changed or stopped. We checked the proportional hazard
assumption with Schoenfeld residuals and by using graphical
methods. No violation was found.
We also studied the impact of specific minor PI mutations on
virological outcome. Here, only mutations with a prevalence
$5% were considered. Despite this restriction, the number of
events for some mutations was quite small, particularly the
number of virological failures. Therefore, we used other methods
that can deal better with rare events. It was shown that
propensity scores are a good alternative to control for imbalances
between groups when there are only small numbers of events per
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each patient the propensity of being in the group with or without
minor PI mutation. This was done by calculating propensity
scores with multivariable logistic regression models adjusted for
baseline HIV-1 RNA level, baseline CD4 cell count, ethnicity,
sex, transmission category, calendar year of ART start, presence
of NRTI mutations and the PI used. We validated if the
propensity scores balanced the differences between groups
adequately. Therefore, we performed logistic regression models
adjusted for the propensity score to test if there were still
imbalanced co-variables that were significantly associated with a
group after adjustment. No poorly balanced co-variables were
found. We did not use c statistics for model building of
propensity score methods because it might be inadequate
[25,26]. In a second step, we used the propensity scores for
regression adjustment. The virological outcomes were analyzed
with a Cox regression models adjusted for the log-transformed
propensity score as the single co-variable. The log transformation
is necessary for the adjustment because the variance of
propensity scores needs to be similar between patients with and
without minor PI mutations [27,28].
The accumulation of major PI mutations at the time of
virological failure was compared with Fisher’s exact test.
Statistical analyses were performed with Stata 11 (StataCorp,
College Station, TX).
Table 1. Baseline characteristics.
Characteristics $1 minor PI mutation No minor PI mutation P *
Sex .227
Male 640 (82.9%) 342 (80.1%)
Female 132 (17.1%) 85 (19.9%)
Ethnicity .149
White 701 (90.8%) 398 (93.2%)
Other 71 (9.2%) 29 (6.8%)
Transmission category .020
Men who have sex with men 426 (55.2%) 213 (49.9%)
Heterosexual 187 (24.2%) 111 (26.0%)
Intravenous drug use 129 (16.7%) 95 (22.3%)
Other 30 (3.9%) 8 (1.9%)
Median [IQR] age 45 [39–51] 45 [39–51] .984
HIV-1 RNA .263
,10,000 copies/mL 133 (17.2%) 70 (16.4%)
10,000–99,999 copies/mL 278 (36.0%) 174 (40.8%)
.100000 copies/mL 361 (46.8%) 183 (42.9%)
Median [IQR] log10 HIV-1 RNA 4.9 [4.4–5.5] 4.9 [4.3–5.4] .315
CD4 cell count .024
,200 cells/mL 334 (43.3%) 156 (36.5%)
200–300 cells/mL 253 (32.8%) 141 (33.0%)
.350 cells/mL 185 (24.0%) 130 (30.4%)
Median (IQR) CD4 cells/mL 223 [125.5–339.5] 255 [141–379] .010
CDC stage C 137 (17.8%) 65 (15.2%) .264
NRTI mutation 33 (4.3%) 12 (2.8%) .201
Administered PIs ,.001
unboosted PIs 136 (17.6%) 119 (27.9%)
boosted PIs 636 (82.4%) 308 (72.1%)
Specific PI ,.001
Nelfinavir 115 (14.9%) 105 (24.6%)
Other unboosted PIs 21 (2.7%) 14 (3.3%)
Lopinavir 415 (53.8%) 175 (41.0%)
Atazanavir/r 193 (25.0%) 53 (12.4%)
Indinavir/r 23 (3.0%) 20 (4.7%)
Other boosted PIs 5 (0.7%) 60 (14.1%)
Median [IQR] year of ART start 2006 [2003–2008] 2005 [2001–2008] .005
P* Fishers exact p value for categorical variable and Wilcoxon rank sum for continuous variables.
Abbreviations: ART, antiretroviral therapy; CDC, Centers for Disease Control and Prevention; IQR, interquartile range; NRTI nucleoside reverse transcriptase inhibitor; PI,
protease inhibitor.
doi:10.1371/journal.pone.0037983.t001
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Study Population and Baseline Characteristics
In the SHCS, 1265 subtype B-infected patients started first-line
ART with a PI and 2 NRTIs and had a resistance test performed
while ART-naı ¨ve. Patients were excluded from analysis if they had
major PI mutations detected (n=1), missing baseline HIV-1 RNA
levels or CD4 cell counts (n=14), or no HIV-1 RNA follow-up
before the first ART change (n=51). Finally, 1199 of 1265
patients (94.8%) were included to study the time to viral
suppression. In table 1, we showed the baseline characteristics.
Minor PI mutations were highly prevalent and present among 772
(64.4%) patients. Slightly more patients with a minor PI mutation
were treated with a boosted PI, 82.4% compared to 72.1%
without minor PI mutation (P,.001).The median CD4 cell count
was higher among patients without minor PI mutation, 255 cells/
mL compared to 223 cells/mL( P=.010). The most common NRTI
combinations were lamivudine/zidovudine (43.3%), emtricita-
bine/tenofovir (33.2%) and lamivudine/abacavir (9.6%), no
differences were observed between patients with and without
minor PI mutations. 869 patients (72.5%) had the required
minimum follow-up time to study the time to virological failure.
Baseline characteristics of excluded patients did not markedly
differ except that excluded patients started ART earlier (median:
2005 compared to 2006, P=.006).
Prevalence of Specific Minor PI Mutations
The prevalence of the most common minor PI mutations
related the respective administered PI therapies is shown in
Figure 1. L63P was the most common minor PI mutation, it was
present among 351 of 618 (56.8%) patients before treatment with
lopinavir. Followed by the atazanavir related mutation I93L
(41.2%, n=114/277), the atazanavir/saquinavir related mutation
I62V (n=84/288, 29.2%) and the indinavir/nelfinavir/saquinavir
related mutation V77I (n=85/313, 27.2%). L10I and M36I were
found to be associated with a worse treatment in previous studies
[14,15]. In our study, they occurred in 9.7% (n=118/1218) and
13.6% (n=79/579) samples, respectively. The following muta-
tions had a prevalence of ,5%: L10F (0.2%)/R (0%)/V(1.9%),
V11I (0%), K20I (0%)/M (0.4%)/R (2.3%)/T (0%)/V (0%), L24I
(0.1%), V32I (0%), L33F (0.4%)/I (1.4%)/V (2.9%), E34Q (0%),
E36L (1.1%)/V (0.4%), M46I (0.2%)/L (0%), I47V (0%), G48V
(0%), I50V (0%), F53L (0%)/Y (0%), I54A (0%)/L (0%)/M (0%)/
S (0%)/T (0%)/V (0.2%), I64M (2.5%)/L (2.5%), A71I (0%)/L
(0%), G73A (0%)/C (0%)/S (0%)/T (0%), T74P (0%), V82A
(0.2%)/F (0%)/I (1.1%)/S (0%)/T (0.2%), I84V (0%), L90M
(1.0%), and I93M (0%). Overall, 41.7%, 16.1%, 4.7% and 1.9% of
patients had 1, 2, 3 and $4 minor PI mutations related to first-line
ART.
Virological Outcome
The time to viral suppression and the time to virological failure
were similar between patients with and without minor PI
Figure 1. Prevalence of minor protease inhibitor (PI) mutations. Minor PI mutations with a prevalence $5% and PI treatments potentially
related to these mutations [22]. Error bars represent 95% confidence interval.
doi:10.1371/journal.pone.0037983.g001
Figure 2. Kaplan-Meier curves. Kaplan-Meier curves comparing (A)
time to viral suppression and (B) time to virological failure between
patients with $1 and without minor protease inhibitor (PI) mutations
detected.
doi:10.1371/journal.pone.0037983.g002
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relevant differences. As shown in Table 2, univariable and
multivariable hazard ratios (HR) were 1.1 (95% CI:.9–1.2) and
1.1 (95% CI: 1.0–1.3) when comparing the time to viral
suppression between patients with and without minor PI
mutations. A HR below 1 would indicate a longer time to viral
suppression among patients carrying viruses with a minor PI
mutation. Also the time to virological failure was not significantly
different between patients with and without minor PI mutations,
univariable and multivariable HRs were 1.0 (95% CI: 0.6–1.9)
and 0.9 (95% CI: 0.5–1.6), respectively. The risk for a virological
failure would be increased among patients detected with a minor
PI mutation if the HR was above 1.
Additionally, we studied the impact of the number of minor PI
mutations on the virological outcome. Compared to patients
without minor PI mutations, HRs of the time to viral suppression
were 1.1 (95% CI: 0.9–1.2), 1.1 (95% CI: 0.9–1.4), 1.5 (95% CI:
1.1–2.1) and 1.4 (95% CI: 0.9–2.3) for patients with 1, 2, 3, $4
minor PI mutations, respectively. For the time to virological failure
HRs were 1.1 (95% CI: 0.6–1.8), 0.5 (95% CI: 0.2–1.5), 0.3 (0.1–
3.8) and 1.0 (0.1–10.3) for patients with 1, 2, 3, $4 minor PI
mutations, respectively. Comparing patients with ,3 and $3
minor PI mutations did not alter conclusions, the HR for the time
to viral suppression was 1.2 (95% CI: 0.9–1.4) and for the time to
virological failure 0.6 (95% CI: 0.2–2.0).
We additionally studied the effect of specific minor PI mutations
on the virological outcome. No specific minor PI mutation was
associated with a worse treatment outcome (Figure 3). We studied
all minor PI mutations with a prevalence $5%. The 95%
confidence interval of HRs always included 1, meaning that no
significant differences were observed between patients with and
without minor PI mutations.
We performed a sensitivity analyses and ran separate models for
ART with unboosted PI and boosted PIs. For the time to viral
suppression, multivariable HRs were 1.0 (95% CI: 0.6–1.9) and
1.2 (95% CI: 1.0–1.4) for therapies with unboosted and boosted
PI, respectively. For the time to virological failure, multivariable
HRs were 1.1 (95% CI: 0.6–2.0) and 0.6 (95% CI: 0.2–1.6) for
unboosted and boosted PI therapies, respectively.
Accumulation of Major PI Mutations
The accumulation of major PI mutations was not higher
among patients detected with a minor PI mutation while ART-
naı ¨ve. Of 63 patients who experienced a virological failure on
Table 2. Cox regression models analyzing time to viral suppression and time to virological failure. Models were stratified for the
administered PI.
Viral Suppression Virological failure
Characteristics
univariable HR
(95% CI) P
multivariable HR
(95% CI) P
univariable HR
(95% CI) P
multivariable HR
(95% CI) P
Minor PI mutation
No Ref Ref Ref Ref
Yes 1.1 (0.9–1.2) .364 1.1 (1.0–1.3) .196 1.0 (0.6–1.6) .935 0.9 (0.5–1.6) .765
Sex
Male Ref Ref Ref Ref
Female 1.3 (1.1–1.6) .001 1.3 (1.1–1.5) .003 0.6 (0.3–1.3) .188 0.5 (0.2–1.2) .142
Ethnicity
White Ref Ref Ref Ref
Other 1.3 (1.0–1.6) .020 1.1 (0.9–1.5) .250 1.2 (0.5–3.0) .724 1.2 (0.5–3.3) .690
Age (per 10 years) 1.0 (0.9–1.0) .366 1.0 (0.9–1.1) .670 0.9 (0.7–1.2) .363 0.9 (0.6–1.2) .374
Transmission category
Other Ref Ref Ref Ref
IDU 1.0 (0.8–1.2) .806 0.9 (0.7–1.1) .188 1.2 (0.7–2.0) .551 1.5 (0.9–2.7) .145
CD4 cell count
,200 cells/ml Ref Ref Ref Ref
200–350 cells/ml 1.2 (1.1–1.4) .009 1.1 (1.0–1.3) .103 0.7 (0.3–1.2) .170 0.6 (0.3–1.2) .125
.350 cells/ml 1.4 (1.2–1.7) ,.001 1.3 (1.1–1.6) .001 1.2 (0.7–2.3) .496 1.3 (0.6–2.5) .500
HIV-1 RNA
,10,000 copies/mL Ref Ref Ref Ref
10,000–99,999 copies/mL 0.7 (0.6–0.8) ,.001 0.7 (0.6–0.9) .001 1.3 (0.6–3.0) .513 1.6 (0.7–4.0) .279
.100,000 copies/mL 0.4 (0.4–0.5) ,.001 0.5 (0.4–0.5) ,.001 1.6 (0.7–3.7) .259 2.3 (0.9–5.8) .081
Year of ART start 1.0 (1.0–1.0) .321 1.0 (1.0–1.0) .325 0.9 (0.8–1.1) .536 1.0 (0.8–1.2) .994
NRTI mutation
No Ref Ref Ref Ref
Yes 1.0 (0.7–1.4) .828 0.7 (0.5–1.1) .106 3.7 (1.6–8.5) .002 6.1 (2.5–15.0) ,.001
Abbreviations: HR, hazard ratio; CI, confidence interval; PI, protease inhibitor; ART, antiretroviral therapy; NRTI, nucleoside reverse transcriptase inhibitor.
doi:10.1371/journal.pone.0037983.t002
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(36.8%) patients without minor PI mutations and 9/24 (37.5%)
accumulated a major mutation, respectively (P=1.000).
Discussion
We found that the presence of minor PI mutations did not
influence the virological outcome of first-line ART in HIV subtype
B infected individuals. The prevalence of some minor PI mutations
was found to be very high. Therefore, it is of great value to know
that these mutations did not exhibit a negative impact on therapy
outcome. In our study, neither the time to viral suppression, nor
the time to virological failure differed between patients with and
without minor PI mutations. Moreover, the risk for the emergence
of a major PI mutation was not increased.
Today, first-line ART often includes non-nucleoside reverse
transcriptase inhibitors, especially in resource-limited settings.
However, PIs may increasingly be needed as good alternatives,
especially in the presence of transmitted drug resistance mutations
which seem to be seriously on the rise in resource-limited settings
[29]. Our findings disproved concerns that the high prevalence of
minor PI mutations limits the use of PIs but it is to mention that we
only focused on subtype B infections.
To our knowledge, this is the largest study analyzing the impact
of minor PI mutations on treatment outcome. We were able to
include 1199 treated patients from the highly representative
dataset of the SHCS. Despite the large number of patients
included, the sample size was too small to perform an analysis for
some specific minor PI mutations. Therefore, we had to restrict the
analysis to the most prevalent minor PI mutations and used the
propensity score method. The regression adjustment with
propensity scores is a good option when the number of exposed
patients is large and the number of events small. This method has
the advantage that the Cox regression only had to be adjusted for
one co-variable, the propensity score. If too many variables are
included in a regression model relative to the number of events,
estimates can be incorrect [30]. However, for some specific minor
PI mutations, the confidence intervals of the HRs were quite large,
especially for the models studying time to virological failure. This
indicates that the accuracy of some estimates is limited.
Unfortunately, we lacked statistical power to compare different
combinations of minor PI mutations. Although we found that the
time to viral suppression was shorter for patients with 3 minor PI
mutations compared to patients without mutations, we think that
the small difference we observed has no clinical relevance or even
may have occurred by chance, considering that the lower bound of
95% CI of the HR was very close to 1, namely 1.1.
Our study supports findings from previous smaller studies that
found no negative impact of minor PI mutations on therapy
outcome [16,17,18]. However, it stands in contrast with the so far
largest published studies by Perno et al including 248 and
93 individuals, respectively [14,15]. They found a higher risk of
virological failure among patients with mutations at position 10
and 36 and a higher accumulation of major PI mutations. In
contrast to our study, Perno et al. included different HIV-1
subtypes and they did not adjust their models for ethnicity.
Ethnicity, however, is potentially an important confounder as it
was found to be associated with treatment outcome in other
studies [31,32]. Furthermore, Perno et al. mainly studied ART
regimens containing unboosted PIs whereas our sample mainly
contains regimens with boosted PIs. However, our sensitivity
analysis that exclusively included ART with unboosted PIs
containing 255 patients also lacked evidence for an impact of
minor PI mutations on treatment outcome.
We convincingly demonstrated that minor PI mutations have
no effect on virological outcome in PI-containing first-line ART, at
least in patients infected by HIV-1 subtype B.
Acknowledgments
We thank the patients who participate in the SHCS; the physicians and
study nurses for excellent patient care; the resistance laboratories for high
quality genotypic drug resistance testing; SmartGene, Zug, Switzerland for
technical support; Brigitte Remy, Martin Rickenbach, MD, F. Scho ¨ni-
Affolter and Yannick Vallet from the SHCS Data Center in Lausanne for
the data management and Marie-Christine Francioli for administrative
assistance. The members of the Swiss HIV Cohort Study: Barth J, Battegay
M, Bernasconi E, Bo ¨ni J, Bucher HC, Burton-Jeangros C, Calmy A,
Cavassini M, Cellerai C, Egger M, Elzi L, Fehr J, Fellay J, Flepp M,
Francioli P (President of the SHCS), Furrer H (Chairman of the Clinical
and Laboratory Committee), Fux CA, Gorgievski M, Gu ¨nthard H
(Chairman of the Scientific Board), Haerry D (deputy of ‘‘Positive
Council’’), Hasse B, Hirsch HH, Hirschel B, Ho ¨sli I, Kahlert C, Kaiser
L, Keiser O, Kind C, Klimkait T, Kovari H, Ledergerber B, Martinetti G,
Martinez de Tejada B, Metzner K, Mu ¨ller N, Nadal D, Pantaleo G, Rauch
A, Regenass S, Rickenbach M (Head of Data Center), Rudin C (Chairman
of the Mother & Child Substudy), Schmid P, Schultze D, Scho ¨ni-Affolter F,
Schu ¨pbach J, Speck R, Taffe ´ P, Tarr P, Telenti A, Trkola A, Vernazza P,
Weber R, Yerly S.
Author Contributions
Performed the experiments: JB SY CC TK. Analyzed the data: AUS VvW
BL. Contributed reagents/materials/analysis tools: HFG AC MC LE PLV
EB HF. Wrote the paper: AUS HFG.
Figure 3. Cox regression models. Univariable (solid circles) and
multivariable (open squares) Cox regression models comparing (A) time
to viral suppression and (B) time to virological failure. 95% confidence
intervals are indicated. The treatment outcome is worse in the presence
of minor protease inhibitor mutations if the hazard ratios lie in the
shaded area.
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